Innsbruck, Austria– Bruker Corporation has announced the acquisition of biocrates life sciences ag, a leading provider of mass spectrometry-based metabolomics solutions headquartered in Innsbruck, Austria. While financial terms were not disclosed, the acquisition marks a significant expansion of Bruker’s footprint in the growing field of multiomics.
biocrates is recognized globally for its standardized metabolomics and lipidomics kits, assays, software, and research services, which support high-throughput, quantitative analysis of more than 1,000 metabolites across 40+ metabolite classes. The company’s technologies are widely used in biomedical, clinical, and pharmaceutical research for metabolite identification, quantification, and data interpretation.
Bruker’s acquisition of biocrates aligns with its broader strategy to become a key provider of multiomics solutions, building on previous acquisitions of proteomics-focused firms PreOmics and Biognosys. By integrating biocrates’ advanced metabolomics platform, Bruker aims to deliver end-to-end solutions encompassing instruments, reagents, software, and analytical services across proteomics, metabolomics, and lipidomics.
“Multiomics is the cornerstone for the future of life sciences, biopharma R&D, and clinical research,” said Dr. Oliver Rinner, Vice President of Enabling Multiomics Solutions at Bruker and founder of Biognosys. “biocrates adds key metabolomics capabilities that, combined with our proteomics tools, will allow us to support customers with a truly integrated multiomics approach.”
Matt Lewis, Ph.D., Bruker’s Vice President for Metabolomics & Lipidomics, emphasized the acquisition’s impact on the company’s scientific direction. “This is a pivotal step in accelerating our metabolomics and lipidomics growth strategy,” he said. “biocrates’ expertise in quantitation and workflow automation will advance our shared vision of making mass spectrometry-based omics more impactful, accessible, and scalable.”
Moritz Seuster, CEO of biocrates, called the acquisition a milestone for the company and a validation of its team’s dedication to advancing quantitative omics. “Joining Bruker gives us the opportunity to scale our mission while remaining committed to innovation and vendor-agnostic solutions,” he said. “Together, we can bring reproducible, quantitative omics tools to more researchers around the world.”
The integration of biocrates into Bruker’s portfolio enhances the company’s capacity to serve the life sciences and clinical research communities with comprehensive, interoperable tools for the next generation of systems biology and precision medicine research.
